In this external validation study of previously proposed molecular subtype classifications for the prediction of survival among CRC patients, we found that MSS cancers with BRAF or KRAS mutations generally conferred a worse prognosis compared to tumors with no such mutations. The gene discussed is BRAF; the disease is cancer.